Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has completed its previously announced registered direct offering.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has completed its previously announced registered direct offering. The company raised $15.3 million in gross proceeds through the sale of 13,939,331 shares of common stock at $1.10 per share.
The net proceeds, after deducting approximately $0.8 million in placement agent fees and other offering expenses, will be used for working capital and general corporate purposes. Canaccord Genuity served as the sole placement agent for the offering.
Positive
- Secured $15.3M in additional funding
- Successfully completed registered direct offering
- Working capital strengthened for operations
Negative
- Share dilution with 13.9M new shares issued
- Offering price of $1.10 indicates significant discount to market
- Additional $0.8M in fees and expenses reducing net proceeds
Details
News Market Reaction – LUCD
The recorded move for LUCD in the trading session of this news was +2.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The gross proceeds to the Company from this offering are approximately
The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.
The securities described above were offered pursuant to a registration statement on Form S-3 (File No. 333-268560), which was declared effective by the Securities and Exchange Commission on December 6, 2022. A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus included in the registration statement may be obtained by contacting Canaccord Genuity LLC, Attention: Syndicate Department, One Post Office Square, Suite 3000,
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering-302393766.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.